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Abstract: The effects of antidepressants on wildlife are currently raising some concern because of an increased number of publications
indicating biological effects at environmentally relevant concentrations (<100 ng/L). These results have been met with some scepticism
because of the higher concentrations required to detect effects in some species and the perceived slowness to therapeutic effects recorded
in humans and other vertebrates. Because their mode of action is thought to be by modulation of the neurotransmitters serotonin,
dopamine, and norepinephrine, aquatic invertebrates that possess transporters and receptors sensitive to activation by these
pharmaceuticals are potentially affected by them. The authors highlight studies on the effects of antidepressants, particularly on
crustacean and molluskan groups, showing that they are susceptible to a wide variety of neuroendocrine disruptions at environmentally
relevant concentrations. Interestingly, some effects observed in these species can be observed within minutes to hours of exposure. For
example, exposure of amphipod crustaceans to several selective serotonin reuptake inhibitors can invoke changes in swimming behavior
within hours. In mollusks, exposure to selective serotonin reuptake inhibitors can induce spawning in male and female mussels and foot
detachment in snails withinminutes of exposure. In the light of new studies indicating effects on the human brain from selective serotonin
reuptake inhibitors using magnetic resonance imaging scans, the authors discuss possible reasons for the discrepancy in former results in
relation to the read-across hypothesis, variation in biomarkers used, modes of uptake, phylogenetic distance, and the afﬁnity to different
targets and differential sensitivity to receptors. Environ Toxicol Chem 2016;35:794–798. # 2015 The Authors. Environmental
Toxicology and Chemistry published by Wiley Periodicals, Inc. on behalf of SETAC.
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INTRODUCTION
Several recent studies have raised concerns that antidepres-
sants in aquatic ecosystems may be an environmental concern
[1–6]. Prescriptions for antidepressants have been increasing
rapidly in some countries [7], with studies indicating that
antidepressants are taken by 1 in 10 of the population [8]. These
drugs are used to treat a wide range of conditions, such as
depression, anxiety, and bipolar disorders [9]. A wide range of
antidepressants are currently in medical use, which include
some of the older prescribed tricyclic compounds (e.g.,
amitriptyline), the selective serotonin reuptake inhibitors
(e.g., ﬂuoxetine), the serotonin and norepinephrine reuptake
inhibitors (e.g., venlaﬂaxine), and the serotonin antagonist and
reuptake inhibitors (e.g., trazodone).
Concentrations of antidepressants in water bodies vary
considerably but have been detected in freshwater [3,10–14],
groundwater [15], and seawater [16]. In arid and semiarid parts
of the world, ephemeral streams can be dominated by municipal
and/or industrial efﬂuent discharges, particularly in urbanized
watersheds [17]. Therefore, some aquatic organisms are likely
to be receiving relatively high and constant exposure to
serotonergic and neurologically active drugs. Furthermore,
recent studies have shown the capacity of aquatic organisms to
bioaccumulate these compounds [18–21]. Despite the wide-
spread presence of antidepressants in the aquatic environment,
their bioactive properties (both neruological and hormonal),
their capacity to bioaccumulate in tissues, and relatively similar
prescription rates of the concentraceptive pill, it was recently
highlighted that the body of research on synthetic estrogen
exposure hugely outweighs the amount currently known for
neurological drugs [22].
EFFECTS IN WILDLIFE AT ENVIRONMENTALLY
RELEVANT CONCENTRATIONS
The concentrations of antidepressants in the aquatic
environment range from nanograms to micrograms per liter,
with most studies reporting concentrations below 100 ng/L. The
scientiﬁc literature has increased in the number of publications
highlighting effects of antidepressants observed at very low
environmentally relevant concentrations [6]. These include
induction of spawning in bivalves [23,24]; altered cyclic
adenosine 30,50-monophosphate/protein kinase A pathway and
serotonin (5-hydroxytryptamine [5-HT]) expression in mussels
[25]; altered mobility in snails [26]; altered memory, cognitive
function, and ability to camouﬂage in cuttleﬁsh [27,28]; induced
phototaxis and altered activity in amphipods [4,29–31]; gene
expression of putative serotonergic pathways in amphipods
[31]; and altered reproduction [21], activity [32], and
embryonic/development endpoints [33] in ﬁsh. Therefore, one
might conclude that the effects of these compounds are diverse
and potentially impact a wide range of invertebrate and
vertebrate phyla.
Fong and Ford [6] recently highlighted that many of these
studies report nonmonotonic concentration–response curves
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[6,31–33]. The low-dose effects reported by some studies have
been questioned as to whether they are in fact artifacts and
whether they are repeatable [34]. Several studies have also been
criticized because of limitations in study design, including use
of novel biomarkers, large interspecies variability, nominal
concentrations, and low numbers of concentrations used
[34,35]. Therefore, calls [22] have been made for laboratories
to repeat their studies and those of others to appropriately assess
the risk posed by these compounds. Vandenburg et al. [36]
recently conducted a large review of cell culture, animal, and
epidemiology studies and concluded that nonmonotonic
responses and low-dose effects are remarkably common in
studies of natural hormones and endocrine-disrupting chem-
icals. They went on to suggest that fundamental changes in
chemical testing and safety determination are needed to protect
human health. Accepting some of the limitations of recent
studies, it seems reasonable to assume that hormetic effects
might also be found in serotonergic drugs.
ARE RAPID EFFECTS THAT UNUSUAL?
One of the most intriguing results of some of the reported
studies is that effects can sometimes be observed in very short
periods of time [31]. Zebra mussels can be signiﬁcantly induced
to spawn within minutes of both ﬂuoxetine and ﬂuvoxamine
exposure at concentrations as low as 300 ng/L and 430 ng/L,
respectively. For example, Fong [23] found that 70% of male
zebra mussels could be induced to spawn in 1 h or less in 1 nM
(430 ng/L) ﬂuvoxamine. Altered oocyte and spermatozoan
densities were observed in zebra mussels exposed to ﬂuoxetine
at 20 ng/L and 200 ng/L following several days of exposure
[24]. Several studies have looked at the effects of ﬂuoxetine on
activity measurements in amphipods and similarly found effects
within very short time frames [6,29–31]. For example, within
less than 2 h of exposure, the freshwater amphipod Gammarus
pulex display altered activity measured following exposure to
ﬂuoxetine at low concentrations [29,30]. The experimental
protocol used a 30-min acclimation period followed by a 1.5-h
recording using electrical conductance induced by the organ-
ism’s movement. The greatest effects on activity were observed
at 10 ng/L to 100 ng/L ﬂuoxetine. In another study using the
marine/estuarine amphipod Echinogammarus marinus, the
authors recorded increased positive phototaxis and decreased
geotaxis following ﬂuoxetine exposure for 1 wk, with the
greatest effects observed at 10 ng/L to 100 ng/L [4]. These
behavioral effects were also observed following 2-wk and 3-wk
exposures. The behavioral effects recorded in the amphipods
corresponded to those when exposed to serotonin (5-HT) or
infected with serotonin-modulating parasites. Using an alterna-
tive method of behavioral analysis, the activity of E. marinus
was recorded using Daniovision (Noldus) with Ethovion XT
software (Ver 8.1) following exposure to the selective serotonin
reuptake inhibitors sertraline and ﬂuoxetine [31]. Signiﬁcant
effects on amphipod activity (velocity in millimeters per
second) were recorded after 1 d for ﬂuoxetine and both 1 h and
1 d for sertraline. Similarly, the greatest effects were observed at
100 ng/L, with exposed organisms displaying elevated veloci-
ties under both dark and light conditions. Following 8-d
exposure, there was a signiﬁcant down-regulation of genes with
putative serotonergic function for ﬂuoxetine (but not sertraline)
at 1 ng/L and 10 ng/L. It is important to note that neither
ﬂuoxetine nor sertraline elicited effects on velocity after 8 d.
Therefore, albeit with nominal concentrations and the relatively
few studies done to date, there is some repeatability in the low-
dose effects observed.
Although we believe many of the observed effects can be
attributed to different modes of action and not exclusively to 5-
HT reuptake inhibition, it is important to mention the role of pH
on the toxicokinetics and uptake of antidepressants. Several
recent studies have highlighted that changes in pH can strongly
inﬂuence the ionization of antidepressants, resulting in different
uptake rates and consequently toxicity [37–42]. Noteworthy is
the increased toxicity observed at higher pH.
Although the pH of the medium is undoubtedly important
because the hydrophobicity of the compound would affect
its ability to cross membranes and enter cells, the route of
uptake and the mechanism of action would determine the target
tissues and cell membranes to cross. The route of uptake of
antidepressants in aquatic vertebrates such as ﬁshes is likely
through the gills or oral cavity. Once in the blood, and if capable,
they would cross the blood–brain barrier, enter the brain, and
exert action by blocking reuptake of 5-HT there. Aquatic
anurans, on the other hand, would be capable of gill or cutaneous
uptake before the antidepressant enters the blood. Brooks [43]
reported that, using probabilistic hazard assessment and ﬁsh
plasma modeling approaches, selective serotonin reuptake
inhibitors and tricyclic antidepressants are predicted to result
in therapeutic hazard to ﬁsh (internal ﬁsh plasma level equalling
mammalian therapeutic dose) when exposed to water (inhala-
tional) at or below 1mg/L. However, Brooks [43] also stated that
because of data limitations we do not know the internal doses of
therapeutic or side effects of drugs in ﬁsh or invertebrates.
By contrast, the route of antidepressant uptake in inverte-
brates is likely to vary with taxonomic group. In bivalve
mollusks, the route of uptake could be direct internalization via
the gills. However, because bivalves ﬁlter water, the entire
mantle cavity containing the gonads, foot, digestive gland, and
adductor muscles, as well as the gills, would be exposed to the
water where contact with external receptors would be possible.
Matsutani and Nomura [44] have shown that isolated fragments
of scallop ovaries will release eggs when treated with 5-HT,
suggesting that 5-HT receptors are located directly on the
gonad. Isolated mussel siphons and mantle tissues can also be
induced to contract and relax with externally applied 5-HT, and
these responses can be mimicked by vertebrate 5-HT2 receptor
ligands, again suggesting the presence of 5-HT receptors
directly on the siphon and mantle [45]. Similar to bivalves,
aquatic snails with gills (prosobranchs) or a modiﬁed lung
(pulmonates) could take up antidepressants via these respiratory
surfaces, but the foot and all tissues within the mantle cavities
are also available surfaces for uptake.
In crustaceans with a heavy exoskeleton that covers most
of their body like crabs, crayﬁsh, and shrimps, antidepressants
could become internalized via the branchial cavity and then
enter the hemocoelomic cavity; but in others that lack gills
antidepressants would have to get across the general body
surface. Once in the hemocoelomic cavity they can come
directly in contact with thoracic and abdominal ganglia of the
ventral nerve cord both receptive to and capable of producing 5-
HT [46–48]. In planktonic crustaceans with a thin exoskeleton
and a large surface area to volume ratio such asDaphnia, uptake
could occur via the feeding current into the ﬁltering chamber;
but a major site of respiratory gas exchange occurs at the inner
wall of the carapace [49]. Marine worms can have elaborate
uptake structures, such as parapodia, tentacles, gills, and palps
[50]; and uptake could be through those structures, across the
general body surface, or via ingestion.
Recently, Karlsson et al. [40] examined the route of uptake of
the pharmaceuticals triclosan, diclofen, and ﬂuoxetine into the
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aquatic oligochaete Lumbriculus variegatus. In this worm, the
route of uptake could either be integumental or through the oral
cavity, and they cleverly used an oligochaete that regenerates
head and tail segments; thus, head removal would inhibit
ingestion but not integumental uptake. They found that there
was no signiﬁcant difference in uptake of 14C-labeled ﬂuoxetine
between feeding and nonfeeding (headless) worms, although
they did ﬁnd that the antibiotic triclosan was taken up more by
feeding worms. Their results indicate that even for an aquatic
organism like an oligochaete, there could be multiple routes of
uptake and, therefore, the effect of pH on the speed of an
antidepressant-induced response depends on the target cells and
tissues. The behavioral responses that workers are measuring
(e.g., spawning in bivalves, locomotion in snails, phototaxis in
amphipods, learning and cognition in cephalopods, fecundity in
Daphnia) would all be affected by the route of uptake and mode
of action.
Thus, how quickly a response to antidepressants occurs is
likely to be dependent on not only pH but also whether the drug
binds to external receptors or is somehow internalized ﬁrst,
travels through blood vessels, makes its way into a coelomic or
hemocoelomic cavity, and then binds to potentially a multitude
of molecular targets.
ANTIDEPRESSANTS AND THE READ-ACROSS HYPOTHESIS
The read-across hypothesis [51] suggests that a drugwill have
an effect in nontarget organismsonly if themolecular targets have
been conserved, resulting in speciﬁc pharmacological effects
only if plasma concentrations are similar to human therapeutic
concentrations [52]. One of the speciﬁc concerns of recent low-
concentration antidepressant studies is that effect concentrations
do not appear tomatch the read-across hypothesis for therapeutic
dose concentrations for humans [35]. Fluoxetine is generally
prescribed over many weeks to allow for brain concentrations to
rise enough to a concentration whereby beneﬁcial results are
observed in the patients (usually within 1 mo [35]). Therefore, it
has been highlighted [34] that the antidepressant concentrations
in the water of some of these studies are unlikely to produce a
concentration of ﬂuoxetine in the nerve synapses matching the
therapeutic dose for humans (50–500 mg/L plasma concentra-
tion). A recent study nicely demonstrated that fathead minnows
only responded in a tank diving test to measure anxiolytic
behaviors when plasma concentrations of ﬂuoxetine were within
a concentration range similar to or higher than those of human
therapeutic doses [53]. The authors concluded that their study
represents the ﬁrst direct evidence of a measured internal dose-
response effect of a pharmaceutical in ﬁsh, thereby validating the
read-across hypothesis for this compound. This was indeed an
eloquent study that clearly demonstrated that the endpoints
observedwithin theﬁsh (ﬁsh anxiety tests)matched those close to
human therapeutic plasma concentrations. How surprised might
we have been if they were very much different? Human
therapeutic doses, particularly for antidepressants, are often
derived from questionnaires given to patients posttreatment,
which have themselves been subject to criticism [54]. Therefore,
we must be careful about “what” we are reading across when
interpreting the read-across hypothesis, especially when inter-
preting disparate endpoints. This is especially true when drugs
may have multiple targets, different afﬁnities for targets in
different organisms, or similar biological targets controlling
different biological responses [23].
The evolution of the vertebrates represents a minute time
frame in history compared with the biological divergence of the
invertebrates and their targets for 5-HT and serotonin-like
drugs. There are a number of possible targets for antidepressants
such as ﬂuoxetine in both vertebrates and invertebrates other
than 5-HT reuptake transporters. Ni andMiledi [55] showed that
ﬂuoxetine binds to and blocks 5-HT-2C receptors in frog
(Xenopus) oocytes. They concluded that ﬂuoxetine is a
competitive and reversible receptor antagonist of 5-HT-2C
receptors. Garcia-Colunga et al. [56] showed that ﬂuoxetine
blocks both muscle and neuronal nicotinic acetylcholine
receptors. Indeed, the “selectivity” of selective serotonin
reuptake inhibitors and serotonin and norepinephrine reuptake
inhibitors has been questioned by clinical psychopharmacolo-
gists for many years. These drugs show binding afﬁnity not only
to 5-HT-2C receptors but to dopamine reuptake transporters,
muscarinic cholinergic receptors, sigma receptors, and enzymes
such as nitric oxide synthase and a variety of cytochrome P450s
[57]. Recently, studies on 5-HT receptors and 5-HT transporters
in the nematode Caenorhabditis elegans have suggested that
antidepressants such as ﬂuoxetine do not act as selective
serotonin reuptake inhibitors. Ranganathan et al. [58] found that
ﬂuoxetine induces responses in C. elegans that lack a 5-HT
transporter (mod-5). They suggest that ﬂuoxetine could be
acting independently of 5-HT and any 5-HT transporter. That
study conﬁrmed the earlier work by Choy and Thomas [59],
who found that ﬂuoxetine induces neuromuscular activity in the
anterior region of C. elegans in 5-HT–deﬁcient mutants and
suggest that drugs like ﬂuoxetine have targets other than 5-HT
reuptake transporters. Dempsey [60] showed that ﬂuoxetine
stimulates egg laying in C. elegans independent of 5-HT and
independent of the 5-HT transporter. Kullyev et al. [61]
demonstrated that ﬂuoxetine binds directly to G protein–
coupled 5-HT receptors in C. elegans. It should be noted that
5-HT transporters have been identiﬁed in all major invertebrate
phyla [62]. The G protein–coupled 5-HT receptors may have
evolved over 750 million years ago, whereas mammalian 5-HT
receptor subtypes may have differentiated 90 million years
ago [63]. Thus, the number and type of potential targets of
these drugs and the cellular responses to them are likely to
be as diverse as the groups of organisms in which they
evolved. Therefore, we must be careful when matching
endpoints over large phylogenetic distances even when the
biological systems such as the nervous system are relatively
conserved, a point made in several studies [17,34,35,51,52].
This is especially true when some endpoints are unfeasible
to read across, such as serotonin/dopamine-modulated camou-
ﬂage or photosensitivity. A recent human-based study has
highlighted that a biological response to antidepressants
(escitalopram) could be detected following a single dose
(20mg) within several hours using resting-state functional
magnetic resonance imaging [64]. The authors observed that the
single dose of a serotonin reuptake inhibitor dramatically alters
functional connectivity throughout the brain in healthy subjects.
Speciﬁcally, their analysis suggested a widespread decrease in
connectivity in most cortical and subcortical areas of the brain.
Therefore, some effects of antidepressants in humans are
detectable quite rapidly following antidepressants when
measuring more sensitive endpoints. In this instance the plasma
concentrations of escitalopram were 25 13 ng/mL, which is
not uncommon for this particular selective serotonin reuptake
inhibitor; but steady-state concentrations are usually observed
following 7 d to 10 d and clinical signs of effects following
1 wk to 2 wk [65,66]. Therefore, biologically detectable
endpoints might be quite different from human therapeutic
dose concentrations but still have unknown biological
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disruption, which is an important distinction in environmental
protection.
SUMMARY
Antidepressants are ubiquitous in aquatic environments
impacted by sewage efﬂuent. Although the number of studies
assessing their potential for environmental impact is increasing,
they remain few in number and insufﬁcient to enable us to fully
understand the ecological risk posed by these compounds.
Those studies that have been published show quite variable
effect concentrations, and some have limitations in their
experimental designs. There does, however, appear to be
mounting evidence that very low concentrations can impact the
biological function of multiple aquatic organisms. Several
studies have recorded the rapid action of antidepressants on
some aquatic species; coupled with this, nonmonotonic
concentration–response curves have been observed, which
suggests that careful consideration must be taken in experimen-
tal design and recording. Given that some aquatic organisms are
likely to be exposed either continuously or sporadically
throughout their life histories, especially during critical life
stages, it will be important to ascertain the long-term impacts of
serotonergic drugs on neural development. Although we have
provided strong evidence that we must be cautious when
applying the read-across hypothesis to distant invertebrates,
evidence from mammalian models does point to the fact that
long-term exposure to antidepressants may cause damage to
neural receptors and architecture. The physiological and
behavioral implications of these changes will be a future
challenge for environmental toxicologists.
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